延胡索颗粒联合奥施康定治疗癌性疼痛的疗效观察

发布时间：2018-06-02 19:36

  本文选题：延胡索颗粒 + 奥施康定　； 参考：《湖北中医药大学》2017年硕士论文

【摘要】：目的观察延胡索颗粒联合奥施康定治疗肿瘤患者的癌性疼通的疗效;研究其对癌性疼痛患者缓解情况及生活质量改善情况,评价临床使用的安全性;同时探讨祖国医学对癌性疼痛的认识及治疗策略,寻找二者在治疗肿瘤相关性疼痛的结合点。方法选取来自于湖北省武汉市四医院肿瘤科就诊并且时间是在2016年1月至2016年10月期间的肿瘤相关性中度疼痛患者54例,均经NRS评分为中度(4-7分)慢性癌痛的患者。将入组的病人用电脑随机分为两组,实验组(即延胡索颗粒组)31例,对照组(奥施康定组)23例。所有患者在性别、年龄、临床分期、病理类型及体力状况(Karnofsky评分)上均无明显差异(P0.05)。对照组:予以初始稳态剂量(疼痛评分48小时内≤3分)奥施康定片20mg Q12h吞服,勿掰开嚼服、含服等。根据疼痛情况进行滴定,连续用药4周;观察组:在治疗组的基础上,观察组加用延胡索颗粒2袋/次,即1g/次Q12h,根据患者疼痛情况进行滴定,连续用药四周。治疗前后检查患者常规体检指标,如血象、肝肾功能等;治疗后对比两组患者疼痛缓解率,不良反应发生率及生活质量改善情况。结果两组患者在治疗四周后,观察组的疼痛控制率为74.19%,对照组的疼痛控制率为52.17%;两组患者在疼痛缓解率上有显著差异(P0.05);观察组的不良反应明显低于对照组,观察组不良反应为54.84%,对照组为91.31%,二者在统计学上有显著差异(P0.05)。在改善生活质量方面,两组疗效相当,无明显差异(P0.05)。结论延胡索颗粒联合奥施康定能明显改善中度癌痛患者的疼痛症状,能较好的减少暴发痛次数从而减少阿片类药物的用量,能明显减轻奥施康定引起的不良反应。
[Abstract]:Objective to observe the curative effect of Yanhusuo granule combined with Oshkangding in the treatment of cancer patients with cancer pain, to study the relief of cancer pain and the improvement of quality of life, and to evaluate the safety of clinical use. At the same time, the understanding and treatment strategy of cancer pain in traditional Chinese medicine were discussed, and the combination of them in the treatment of cancer related pain was found. Methods from January 2016 to October 2016, 54 patients with moderate tumor-related pain were selected from the Department of Oncology, four Hospitals in Wuhan, Hubei Province. All patients were evaluated with NRS score of 4-7) with chronic cancer pain. The patients in the group were randomly divided into two groups: the experimental group (31 cases of Yanhusuo granule group) and the control group (Oshkangding group of 23 cases). There was no significant difference in sex, age, clinical stage, pathological type and physical status in all patients (P 0.05). Control group: the initial steady-state dose (pain score 鈮，

本文编号：1969936